OverviewSuggest Edit

Orchard Therapeutics is a biotechnology company, develops and commercializes transformative ex-vivo autologous hematopoietic stem cell gene therapy to restore normal gene function in primary immune deficiencies, metabolic diseases, and hematological disorders. The сompany also develops adenosine deaminase severe combined immunodeficiency, mucopolysaccharidosis type IIIA, and ex-vivo lentiviral gene therapy programs.
TypePublic
Founded2015
HQLondon, GB
Websiteorchard-tx.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Dec 2019)252
Revenue (FY, 2018)£1.7 M
Share Price (Oct 2020)$4.5 (+8%)
Cybersecurity ratingBMore

Key People/Management at Orchard Therapeutics

Bobby Gaspar

Bobby Gaspar

Chief Executive Officer, Director
John Cerio

John Cerio

SVP & Global Head of Human Resources
Anne Dupraz-Poiseau

Anne Dupraz-Poiseau

Chief Regulatory Officer
Adrien Lemoine

Adrien Lemoine

Chief Business Officer
Kathryn Payne

Kathryn Payne

SVP, Corporate Communications & External Affairs
John Ilett

John Ilett

Chief of Staff, Chief Legal Officer & Company Secretary
Show more

Orchard Therapeutics Office Locations

Orchard Therapeutics has offices in London, Boston, Foster City and Menlo Park
London, GB (HQ)
108 Cannon St
Boston, US
101 Seaport Blvd 7th floor
Boston, US
2 Seaport Ln 8th floor
Foster City, US
1118 Chess Dr
Menlo Park, US
1360 O'Brien Dr
Show all (5)

Orchard Therapeutics Financials and Metrics

Orchard Therapeutics Revenue

Orchard Therapeutics's revenue was reported to be £1.66 m in FY, 2018
GBP

Revenue (FY, 2018)

1.7m

Gross profit (FY, 2018)

1.3m

Gross profit margin (FY, 2018), %

79.7%

Net income (FY, 2018)

(184.4m)

EBIT (FY, 2018)

(188.0m)

Market capitalization (16-Oct-2020)

441.0m

Closing stock price (16-Oct-2020)

4.5

Cash (31-Dec-2018)

268.7m

EV

172.4m
Orchard Therapeutics's current market capitalization is $441 m.
GBPFY, 2018

Revenue

1.7m

Cost of goods sold

337.6k

Gross profit

1.3m

Gross profit Margin, %

80%
GBPFY, 2017FY, 2018

Cash

71.9m268.7m

Accounts Receivable

997.6k1.7m

Current Assets

75.4m284.4m
GBPFY, 2017FY, 2018

Cash From Operating Activities

(26.0m)(78.0m)

Cash From Investing Activities

(1.2m)(3.2m)

Cash From Financing Activities

92.6m283.9m

Net Change in Cash

65.3m202.6m
GBPFY, 2017

Financial Leverage

1.1 x
Show all financial metrics

Orchard Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Orchard Therapeutics Online and Social Media Presence

Embed Graph

Orchard Therapeutics News and Updates

Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)

First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants

Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I

BOSTON and LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to OTL-203, an investigational ex vivo autologous hematopoietic stem …

Orchard Therapeutics to Present at Investor Conferences in March

BOSTON and LONDON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today announced that members of the management team will present at the following investor conferences in March:

Orchard Therapeutics Announces Presentation of Clinical Data from Neurometabolic Franchise at 16th Annual WORLD Symposium

BOSTON and LONDON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced upcoming presentations from its neurometabolic franchise at the 16th Annual WORLD Symposium on February 10-13 in Orlando, FL. Accepted abstracts include encore cl…

Orchard Therapeutics Showcases Clinical Data at the 61st American Society of Hematology Annual Meeting

BOSTON and LONDON, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, will be presenting new r…

Orchard Therapeutics Announces Presentation of New Clinical Data for OTL-200 for Metachromatic Leukodystrophy at Upcoming European Society of Gene & Cell Therapy Annual Congress

Initial Results from Cryopreserved Formulation Clinical Trial Accepted as Poster Presentation Initial Results from Cryopreserved Formulation Clinical Trial Accepted as Poster Presentation
Show more

Orchard Therapeutics Blogs

Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results

Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results Content Import Thu, 08/06/2020 - 07:02 Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results August 6, 2020 at 7:00 AM EDT …

Orchard Therapeutics to Present at Wedbush PacGrow Healthcare Virtual Conference

BOSTON and LONDON , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020 at 9:10 AM ET .     A live webcast of the

Orchard Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results

BOSTON and LONDON , July 30, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August 6, 2020 , at 8:00 a.m. ET to review business updates and its second quarter 2020

Next-Generation Gene Therapy Manufacturing: A Key to Long-Term Growth and Sustainability

The post Next-Generation Gene Therapy Manufacturing: A Key to Long-Term Growth and Sustainability appeared first on Orchard Therapeutics.

Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I

Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I Content Import Mon, 07/20/2020 - 07:01 Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I …

Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration

Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration Content Import Thu, 07/09/2020 - 07:01 Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration July 9, 2020 at 7:00 AM EDT Thi…
Show more

Orchard Therapeutics Frequently Asked Questions

  • When was Orchard Therapeutics founded?

    Orchard Therapeutics was founded in 2015.

  • Who are Orchard Therapeutics key executives?

    Orchard Therapeutics's key executives are Bobby Gaspar, John Cerio and Anne Dupraz-Poiseau.

  • How many employees does Orchard Therapeutics have?

    Orchard Therapeutics has 252 employees.

  • What is Orchard Therapeutics revenue?

    Latest Orchard Therapeutics annual revenue is £1.7 m.

  • What is Orchard Therapeutics revenue per employee?

    Latest Orchard Therapeutics revenue per employee is £6.6 k.

  • Who are Orchard Therapeutics competitors?

    Competitors of Orchard Therapeutics include Aevi Genomic Medicine, AID Genomics and Annexon Biosciences.

  • Where is Orchard Therapeutics headquarters?

    Orchard Therapeutics headquarters is located at 108 Cannon St, London.

  • Where are Orchard Therapeutics offices?

    Orchard Therapeutics has offices in London, Boston, Foster City and Menlo Park.

  • How many offices does Orchard Therapeutics have?

    Orchard Therapeutics has 5 offices.